IMPG2 — interphotoreceptor matrix proteoglycan 2

The IMPG2 gene provides instructions for making a protein called interphotoreceptor matrix proteoglycan 2. This protein is an essential building block of a gel-like substance in the eye called the interphotoreceptor matrix. This matrix sits between the light-sensing cells (photoreceptors) and the nourishing layer of cells behind them. The IMPG2 protein acts like a scaffold, helping to hold these layers together and supporting the health and survival of the light-sensing cells, which are crucial for vision. When the IMPG2 gene is mutated, the protein it produces may be faulty or missing entirely. This weakens the supportive matrix in the eye, making the light-sensing cells vulnerable to damage and eventually causing them to die. Depending on the specific type of mutation, this can lead to different types of vision loss. If a person inherits two mutated copies of the gene (one from each parent), it typically causes a severe, early-onset condition called retinitis pigmentosa, which leads to night blindness and a gradual loss of peripheral (side) vision. If a person inherits just one specific type of mutated copy of the IMPG2 gene, it can cause a different condition called vitelliform macular dystrophy. This condition primarily affects the macula, the central part of the retina responsible for sharp, detailed vision, and usually appears later in life. Understanding the specific genetic mutation can help doctors predict how the disease might progress and guide families in understanding the risks for future generations.

Gene description: Encodes a proteoglycan component of the interphotoreceptor matrix, vital for photoreceptor outer segment maintenance and adhesion.

Patient and family guide: The IMPG2 gene provides instructions for making a protein called interphotoreceptor matrix proteoglycan 2. This protein is an essential building block of a gel-like substance in the eye called the interphotoreceptor matrix. This matrix sits between the light-sensing cells (photoreceptors) and the nourishing layer of cells behind them. The IMPG2 protein acts like a scaffold, helping to hold these layers together and supporting the health and survival of the light-sensing cells, which are crucial for vision. When the IMPG2 gene is mutated, the protein it produces may be faulty or missing entirely. This weakens the supportive matrix in the eye, making the light-sensing cells vulnerable to damage and eventually causing them to die. Depending on the specific type of mutation, this can lead to different types of vision loss. If a person inherits two mutated copies of the gene (one from each parent), it typically causes a severe, early-onset condition called retinitis pigmentosa, which leads to night blindness and a gradual loss of peripheral (side) vision. If a person inherits just one specific type of mutated copy of the IMPG2 gene, it can cause a different condition called vitelliform macular dystrophy. This condition primarily affects the macula, the central part of the retina responsible for sharp, detailed vision, and usually appears later in life. Understanding the specific genetic mutation can help doctors predict how the disease might progress and guide families in understanding the risks for future generations.

Gene function: IMPG2 encodes a large chondroitin sulfate proteoglycan that is a major component of the interphotoreceptor matrix (IPM). The IPM is an extracellular matrix that fills the space between the retinal pigment epithelium (RPE) and the photoreceptor outer segments. It plays crucial roles in maintaining the structural integrity of the retina, facilitating nutrient and waste exchange, and supporting the adhesion and orientation of photoreceptor outer segments, which are essential for phototransduction.

Protein structure: The IMPG2 gene encodes a large core protein consisting of 1,241 amino acids. It is a complex proteoglycan characterized by several distinct structural domains. The protein includes a signal peptide for secretion, two SEA (sperm protein, enterokinase, and agrin) domains, two EGF-like (epidermal growth factor-like) domains, and a single transmembrane domain near the C-terminus. The SEA domains are critical for the protein's function and maturation; SEA-1 is a non-proteolytic domain, while SEA-2 is a proteolytic domain involved in the cleavage and processing of the protein. The EGF-like domains contain multiple cysteine residues that form disulfide bonds, essential for maintaining the protein's three-dimensional structure. IMPG2 undergoes extensive post-translational modifications, including glycosylation with chondroitin sulfate and hyaluronan-binding motifs, which are vital for its integration into the extracellular matrix.

Molecular function: The IMPG2 gene encodes the interphotoreceptor matrix proteoglycan 2, a crucial structural component of the interphotoreceptor matrix (IPM). The IPM is a specialized extracellular matrix that occupies the subretinal space between the photoreceptor outer segments and the apical microvilli of the retinal pigment epithelium (RPE). IMPG2 functions as a chondroitin sulfate- and hyaluronan-binding proteoglycan, playing a vital role in organizing and maintaining the structural integrity of this matrix. At the molecular level, IMPG2 interacts with other matrix components, including IMPG1, to form a dynamic scaffold that supports photoreceptor health and function. It is involved in the adhesion between the neural retina and the RPE, facilitates the exchange of metabolites and visual cycle retinoids, and may participate in the maturation and maintenance of photoreceptor outer segments. Loss of IMPG2 function destabilizes the IPM, rendering photoreceptors vulnerable to physical and metabolic stress, ultimately leading to cell death and retinal degeneration.

Expression pattern: The IMPG2 gene is predominantly expressed in the retina, specifically synthesized by both rod and cone photoreceptor cells. It is also expressed in the pineal gland. Within the retina, the IMPG2 protein is secreted into the interphotoreceptor matrix (IPM), the extracellular space located between the photoreceptor outer segments and the retinal pigment epithelium (RPE). During development, IMPG2 expression is crucial for the maturation and organization of the IPM. The protein localizes to the apical region of the photoreceptor cell bodies, near the outer limiting membrane, and extends into the matrix surrounding the inner and outer segments. This specific spatial and temporal expression pattern underscores its vital role in maintaining the structural and functional relationship between photoreceptors and the RPE.

Mutation spectrum: The mutation spectrum of the IMPG2 gene is diverse, encompassing missense, nonsense, frameshift, and splice-site variants, as well as complex alleles. To date, over 80 pathogenic and likely pathogenic variants have been reported in databases such as ClinVar and LOVD. Mutations are distributed throughout the gene, but certain regions, such as the SEA domains and EGF-like domains, are critical for protein function and are frequent sites for pathogenic missense variants. Truncating mutations (nonsense and frameshift) are predominantly associated with the more severe autosomal recessive retinitis pigmentosa phenotype, while specific missense mutations are often linked to the autosomal dominant maculopathy phenotype.

Pathogenic variants: 1. p.Arg838His - A well-characterized missense variant frequently associated with autosomal dominant vitelliform macular dystrophy. 2. p.Gly1961Glu - A common missense variant that can cause structural alterations in the protein, linked to retinal dystrophy. 3. p.Tyr1045Cys - A missense variant located in the EGF-like domain, affecting disulfide bond formation and protein stability. 4. p.Arg223* - A nonsense mutation leading to premature protein truncation, typically associated with severe autosomal recessive retinitis pigmentosa. 5. c.1084+1G>A - A canonical splice-site mutation resulting in aberrant splicing and loss of function, causing early-onset retinitis pigmentosa.

Clinical significance: Mutations in the IMPG2 gene are associated with a spectrum of inherited retinal diseases, primarily autosomal recessive retinitis pigmentosa (RP) and autosomal dominant vitelliform macular dystrophy (VMD). In IMPG2-associated RP, patients typically experience early-onset symptoms, including night blindness and progressive peripheral vision loss, often manifesting in the first two decades of life. This form of RP is frequently accompanied by early macular involvement, ranging from mild pigmentary changes to profound chorioretinal atrophy, which can lead to significant central vision impairment. Conversely, monoallelic (heterozygous) mutations in IMPG2 can cause adult-onset vitelliform macular dystrophy or a milder maculopathy. This condition is characterized by the accumulation of yellowish, vitelliform (egg yolk-like) material in the macula, leading to progressive central vision loss. The penetrance and expressivity of IMPG2-related maculopathy can be highly variable, even within the same family, with some individuals remaining asymptomatic or showing only subtle changes on optical coherence tomography (OCT).

Inheritance: Autosomal Recessive

Chromosomal location: 3q12.1

Genotype-phenotype correlations: There is a distinct genotype-phenotype correlation associated with IMPG2 mutations. Biallelic (homozygous or compound heterozygous) mutations, which often include nonsense, frameshift, or splice-site variants leading to a complete loss of function, are typically associated with early-onset, severe autosomal recessive retinitis pigmentosa. These patients often exhibit significant macular involvement early in the disease course. In contrast, monoallelic (heterozygous) missense mutations are more commonly associated with autosomal dominant vitelliform macular dystrophy or adult-onset maculopathy. These variants may exert a dominant-negative effect or result in haploinsufficiency, leading to a milder phenotype that primarily affects the macula and presents later in life. The specific location of the mutation, such as within the SEA or EGF-like domains, can also influence the severity and specific clinical manifestations of the disease.

Research and therapeutic approaches: Currently, there are no FDA-approved treatments specifically for IMPG2-associated retinal dystrophies. Management is primarily supportive, focusing on low vision aids, regular monitoring, and genetic counseling. However, the identification of the genetic basis of these diseases has paved the way for targeted therapeutic research. Gene therapy is a promising pipeline approach, particularly for the autosomal recessive retinitis pigmentosa phenotype caused by loss-of-function mutations. Adeno-associated virus (AAV)-mediated gene supplementation aims to deliver a functional copy of the IMPG2 gene to the photoreceptors. Preclinical studies in animal models and human retinal organoids are ongoing to evaluate the safety and efficacy of this approach. For the dominant maculopathy phenotype, strategies such as antisense oligonucleotides (ASOs) or CRISPR/Cas9 gene editing are being explored to silence or correct the mutant allele, though these are still in the early stages of development.

Diagnostic testing: Diagnostic testing for IMPG2-related retinal dystrophies typically involves comprehensive genetic testing, such as targeted inherited retinal disease (IRD) gene panels or whole exome sequencing (WES). These approaches can identify both biallelic mutations associated with retinitis pigmentosa and monoallelic mutations linked to vitelliform macular dystrophy. Clinical evaluation using multimodal imaging, including fundus autofluorescence and optical coherence tomography (OCT), is essential to correlate genetic findings with structural retinal changes. Genetic counseling is a critical component of the diagnostic process. For autosomal recessive IMPG2-associated retinitis pigmentosa, parents of an affected individual are obligate carriers, and siblings have a 25% chance of inheriting the condition. In cases of autosomal dominant IMPG2-related maculopathy, affected individuals have a 50% chance of passing the mutation to their offspring, though incomplete penetrance and variable expressivity must be discussed, as not all individuals with the mutation will develop severe vision loss.

Animal models: Mouse models (Impg2 knockout mice) and zebrafish models have been instrumental in studying IMPG2 function. In mice, loss of Impg2 leads to the mislocalization of IMPG1 and gradual degeneration of photoreceptors, mimicking the human retinitis pigmentosa phenotype. These models demonstrate that IMPG2 is essential for the structural integrity of the interphotoreceptor matrix and the survival of photoreceptor cells. Zebrafish models, which have a cone-dominant retina, are also used to study IMPG2 because their retinal structure shares significant similarities with the human macula. Studies in zebrafish have shown that Impg2 is expressed in photoreceptors and is crucial for the proper formation of the interphotoreceptor matrix during development. These animal models provide valuable platforms for testing potential neuroprotective agents and gene therapies.

Population genetics: The carrier frequency of IMPG2 mutations varies among different populations, but overall, it is considered a rare cause of inherited retinal diseases. Studies indicate that IMPG2 mutations account for approximately 1-2% of all retinitis pigmentosa cases and a significant portion of adult-onset vitelliform macular dystrophies. Certain founder mutations may exist in specific isolated populations, leading to a higher local prevalence of IMPG2-associated diseases, though large-scale population-specific data remains limited.

Selected references: 1. Bandah-Rozenfeld D, et al. Mutations in IMPG2, encoding interphotoreceptor matrix proteoglycan 2, cause autosomal-recessive retinitis pigmentosa. Am J Hum Genet, 2010. PMID: 20691403 2. van Huet RAC, et al. IMPG2-associated retinitis pigmentosa displays relatively early macular involvement. Invest Ophthalmol Vis Sci, 2014. PMID: 24894435 3. Birtel J, et al. IMPG2-Related Maculopathy. Am J Ophthalmol, 2024. PMID: 37805001 4. Salido EM, et al. Proteoglycan IMPG2 Shapes the Interphotoreceptor Matrix and Modulates Vision. J Neurosci, 2020. PMID: 32295815 5. Meunier I, et al. Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes. Ophthalmology, 2014. PMID: 25085631 6. Mitchell B, et al. Interphotoreceptor matrix proteoglycans IMPG1 and IMPG2 are proteolytically cleaved. Sci Rep, 2022. PMID: 36104351 7. Mayerl SJ, et al. Human retinal organoids harboring IMPG2 mutations exhibit a photoreceptor outer segment phenotype. Stem Cell Reports, 2022. PMID: 35584693